A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
NCT ID: NCT03730012
Last Updated: 2024-11-29
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
11 participants
INTERVENTIONAL
2019-06-19
2021-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study also evaluated pharmacokinetics (PK), response to treatment, remission and survival. Adverse events (AEs), clinical laboratory results, vital signs, electrocardiograms (ECGs), and Eastern Cooperative Oncology Group (ECOG) performance status scores were also assessed.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Phase 1:
The phase 1 portion of this study was to establish the recommended phase 2 dose (RP2D) of gilteritinib given in combination with atezolizumab.
Phase 2:
The phase 2 portion of the study was to treat participants with gilteritinib and atezolizumab at the RP2D and was to be enrolled in two stages. The first stage was to evaluate the remission rate and if a minimum rate was to be achieved, a second stage of enrollment was to be continued.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gilteritinib 120 mg + Atezolizumab 420 mg
Participants received 120 milligrams (mg) giltertinib (3 tablets of 40 mg) orally, once a day in continuous 28-day cycles in combination with atezolizumab 420 mg adminstered by intravenous infusion (over 60 minutes) once every 2 weeks of 28-day cycle until the participant no longer received clinical benefit from therapy, unacceptable toxicity occurred or the participant met a treatment discontinuation criterion (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab).
gilteritinib
Oral tablet
atezolizumab
Intravenous infusion
Gilteritinib 120 mg + Atezolizumab 840 mg
Participants received 120 mg giltertinib (3 tablets of 40 mg) orally, once a day in continuous 28-day cycles in combination with atezolizumab 840 mg administered by intravenous infusion (over 60 minutes) once every 2 weeks of 28-day cycle until the participant no longer received clinical benefit from therapy, unacceptable toxicity occurred or the participant met a treatment discontinuation criterion (Maximum treatment duration was 126 days for gilteritinib and 70 days for atezolizumab).
gilteritinib
Oral tablet
atezolizumab
Intravenous infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gilteritinib
Oral tablet
atezolizumab
Intravenous infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has defined AML by the World Health Organization (WHO) criteria (2017) and fulfills one of the following:
* Refractory to at least 1 cycle of induction chemotherapy
* Relapsed after achieving remission with a prior therapy
* Subject is positive for FLT3 mutation in bone marrow or blood after completion of the subject's last interventional treatment.
* Subject has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 at screening.
* Subject must meet the following criteria as indicated on the clinical laboratory tests:
* Serum Aspartate aminotransferase (AST) and Alanine Aminotransferease (ALT) ≤ 2.5 x upper limit of normal (ULN)
* Serum total bilirubin (TBL) ≤ 1.5 x ULN
* Serum creatinine ≤ 1.5 x ULN or an estimated glomerular filtration rate of \> 50 mL/min as calculated by the Modification of Diet in Renal Disease equation.
* Subject is suitable for oral administration of study drug.
* A female subject is eligible to participate if she is not pregnant and at least one of the following conditions applies:
* Not a woman of childbearing potential (WOCBP) OR
* WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 180 days after the final study drug administration.
* Female subject must agree not to breastfeed starting at screening and throughout the study period, and for at least 180 days after the final study drug administration.
* Female subject must not donate ova starting at screening and throughout the study period, and for at least 180 days after the final study drug administration.
* A male subject must not donate sperm starting at screening and throughout the treatment period, and for at least 120 days after the final study drug administration.
* A male subject with female partner(s) of child-bearing potential must agree to use contraception during the treatment period, and for at least 120 days after the final study drug administration.
* Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the treatment period, and for 120 days after the final study drug administration.
* Subject agrees not to participate in another investigational study while on treatment.
Exclusion Criteria
* Subject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
* Subject has AML secondary to prior chemotherapy for other neoplasms (except for myelodysplastic syndrome).
* Subject has clinically active central nervous system leukemia.
* Subject has uncontrolled or significant cardiovascular disease, including:
* A myocardial infarction within 12 months
* Uncontrolled angina within 6 months
* History of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, torsades de pointes) or any history of arrhythmia
* Uncontrolled hypertension
* Subject has baseline left ventricular ejection fraction that is ≥ 45%.
* Subject has mean triplicate Fridericia-corrected QT interval (QTcF) \> 450 ms at Screening based on central reading.
* Subject has congenital or acquired Long QT Syndrome at screening.
* Subject has hypokalemia and/or hypomagnesemia at screening.
* Subject has been diagnosed with another malignancy that requires concurrent treatment or hepatic malignancy regardless of the need for treatment.
* Subject has clinically significant coagulation abnormality unless secondary to AML.
* Subject is receiving or plans to receive concomitant chemotherapy or immunotherapy.
* Subject has had major surgery within 4 weeks prior to the first study dose.
* Subject has radiation therapy within 4 weeks prior to the first study dose.
* Subject requires treatment with concomitant drugs that are strong inducers of Cytochrome P450 (CYP3A).
* Subject has known pulmonary disease with diffusion capacity of lung for carbon monoxide ≤ 65%, forced expiratory volume in the first second (FEV1) ≤ 65%, dyspnea at rest or requiring oxygen or any pleural neoplasm.
* Subject with systemic fungal, bacterial, viral or other uncontrolled infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment. Subject needs to be off pressors and have negative blood cultures for 48 hours.
* Subject has not recovered from any prior therapy related toxicities.
* Subject is known to have human immunodeficiency virus infection.
* Subject has active hepatitis B or C or other active hepatic disorder.
* Subject has previously been treated with gilteritinib, quizartinib or crenolanib (will only apply to subjects enrolled in the phase 2 portion of the study).
* Subject has active clinically significant graft-versus-host disease (GVHD) or is on treatment with systemic corticosteroids for GVHD.
* Subject has relapsed after allogeneic hematopoietic stem cell transplant (HCST).
* Subject has an active autoimmune disorder that makes the subject unsuitable for study treatment or participation.
* Subject has any condition that makes the subject unsuitable for study participation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Global Development, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Executive Medical Director
Role: STUDY_DIRECTOR
Astellas Pharma Global Development
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States
University of Chicago
Chicago, Illinois, United States
Northwestern University
Chicago, Illinois, United States
University of Kentucky
Lexington, Kentucky, United States
Roswell Park Cancer Institute (RPCI)
Buffalo, New York, United States
Columbia University Medical Center
New York, New York, United States
Weill Cornell Medical College
New York, New York, United States
The Ohio State University Comprehensive Cancer Center (OSUCCC)
Columbus, Ohio, United States
Vanderbilt Ingram Cancer Center
Nashville, Tennessee, United States
Simmons Comprehensive Cancer Center
Dallas, Texas, United States
University of Texas MD Anderson
Houston, Texas, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Link to results on the Astellas Clinical Study Results website.
Link to plain language summary of the study on the Trial Results Summaries website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2215-CL-1101
Identifier Type: -
Identifier Source: org_study_id